Nicholas J. Short, MD

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

Short summarized the NGS-based MRD findings from his ALL study presented at the 2020 ASH Annual Meeting.

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with oncologist Nicholas J. Short, MD, of the Division of Cancer Medicine at University of Texas MD Anderson Cancer Center, in Houston.